Concert Pharmaceuticals Inc (NASDAQ:CNCE) Director Richard Aldrich sold 30,000 shares of the firm’s stock in a transaction that occurred on Friday, January 19th. The stock was sold at an average price of $19.35, for a total value of $580,500.00. Following the transaction, the director now owns 286,975 shares of the company’s stock, valued at approximately $5,552,966.25. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Richard Aldrich also recently made the following trade(s):

  • On Tuesday, January 16th, Richard Aldrich sold 31,236 shares of Concert Pharmaceuticals stock. The stock was sold at an average price of $19.14, for a total value of $597,857.04.

Concert Pharmaceuticals Inc (NASDAQ CNCE) traded down $0.10 during mid-day trading on Friday, reaching $19.61. The company had a trading volume of 520,386 shares, compared to its average volume of 613,525. Concert Pharmaceuticals Inc has a 12-month low of $8.61 and a 12-month high of $30.71. The firm has a market cap of $444.31, a PE ratio of 5.23 and a beta of 1.67.

Concert Pharmaceuticals (NASDAQ:CNCE) last released its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.16). Concert Pharmaceuticals had a net margin of 62.31% and a negative return on equity of 51.48%. equities analysts expect that Concert Pharmaceuticals Inc will post 4.1 earnings per share for the current year.

Several research firms recently commented on CNCE. TheStreet upgraded Concert Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Monday, January 8th. Mizuho cut Concert Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $23.00 price target for the company. in a report on Friday, January 12th. UBS Group set a $34.00 price target on Concert Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, December 19th. BidaskClub cut Concert Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, December 22nd. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $27.00 price target on shares of Concert Pharmaceuticals in a report on Friday, January 12th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $24.33.

A number of hedge funds have recently added to or reduced their stakes in the stock. Ingalls & Snyder LLC increased its holdings in Concert Pharmaceuticals by 8.7% during the 4th quarter. Ingalls & Snyder LLC now owns 1,314,562 shares of the biotechnology company’s stock valued at $34,008,000 after purchasing an additional 105,500 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Concert Pharmaceuticals in the 4th quarter valued at $7,713,000. Schwab Charles Investment Management Inc. increased its stake in shares of Concert Pharmaceuticals by 14.0% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 36,621 shares of the biotechnology company’s stock valued at $948,000 after buying an additional 4,499 shares during the period. Convergence Investment Partners LLC acquired a new stake in shares of Concert Pharmaceuticals in the 4th quarter valued at $718,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Concert Pharmaceuticals in the 3rd quarter valued at $843,000. 65.29% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Concert Pharmaceuticals Inc (CNCE) Director Sells $580,500.00 in Stock” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2018/01/20/concert-pharmaceuticals-inc-cnce-director-sells-580500-00-in-stock.html.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.